Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops

On Tuesday, Pfizer Inc. (NYSE:PFE) shared topline data from a mid-stage study for a weight loss drug and reported fourth quarter earnings that beat consensus estimates.Weight Loss DataPfizer released data from the Phase 2b VESPER-3 study of monthly maintenance dosing of PF'3944 (MET-097i) in adults with obesity or overweight without type 2 diabetes.The U.S. drug giant added the ultra-long-acting, injectable GLP-1 receptor agonist via a massive $10 billion Metsera, Inc. deal.The ongoing 64-week study demonst ...